Takeda hikes full-year sales despite Actos erosion; NY union sues AbbVie, Teva, alleging pay-for-delay;

@FiercePharma: Behold the patent cliff: U.S. drug market shrinks for first time. Report | Follow @FiercePharma

@EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that is ready to produce products. More | Follow @EricPFierce

> Takeda Pharmaceutical managed to boost sales by 3% for fiscal 2012 to $15.8 billion, despite generic competition for its diabetes blockbuster Actos; its 2011 acquisition of Nycomed helped, though costs related to that buyout put a drag on net profits. Report

> A New York union benefits plan sued AbbVie ($ABBV) and Teva ($TEVA) over a patent settlement that allegedly delayed generic competition for AbbVie's cholesterol drug Niaspan. Report

> Warner Chilcott ($WCRX) said the FDA has approved its new oral contraceptive, as yet unnamed; the company plans to launch the new product in August. Release

> Hungary's Richter posted a 13.7% increase in first-quarter profits, thanks to growth in exports and new stability in its home market. Report

> Alexza Pharmaceuticals shares ($ALXA) jumped on the news that Teva Pharmaceutical Industries had hired on to sell its inhaled antipsychotic drug Adasuve. Report

> Novartis ($NVS) tapped Citigroup to handle the sale of shares in its Indian unit to reduce its stake in compliance with new regulatory guidelines. Report

Medical Device News

@FierceMedDev: Report: ICU weighing billion-dollar sale. Article | Follow @FierceMedDev

@MarkHFierce: Medtronic may have made waves with its renal denervation device, but buyers aren't widespread yet. More | Follow @MarkHFierce

 @DamianFierce: Vermillion is raising $31.5M in equity to market its ovarian cancer diagnostic. Story | Follow @DamianFierce

> Device tax, sluggish demand moves Theragenics Q1 into the red. More

> Nanostim reports early human success with leadless pacer. Story

> Genomic Health rolls out new prostate cancer Dx. DxExtra

Biotech News

@FierceBiotech: Industry Voices: Genomics, Biotechnology's Oldest Next Big Thing by Elizabeth Silverman. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Simos Simeonidis sees a stockholder revolt brewing at $VVUS. Numbers are incredibly ugly and execs have no idea what they are doing. | Follow @JohnCFierce

@RyanMFierce: Receptos made it through the gauntlet to complete $73M IPO, priced at low end of $14-$16 proposed range. Item | Follow @RyanMFierce

> FDA's Hamburg touts rising approval record and promises swifter interaction. Story

> Global CRO Quintiles rakes in $947M as its hot IPO sells at top range. News

> Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb. Article

Vaccines News

> CDC continues to build defenses in H7N9 lull. More

> GSK, Merck agree on HPV vax discount with GAVI. Article

> Heroin vaccine keeps rats clean. Item

> Sanofi sees Shantha Biotech's Shan5 back in 2014. Report

> Takeda takes on Sanofi with $250M dengue buyout. More

Pharma Manufacturing News

> Pediatric drug shortages draw Congressional attention. News

> Hamburg faces Senate as new compounding regulations progress. Story

> Proposed law would delay unit drug tracking for 15 years. More

> Ranbaxy sees tough quarter as it recovers from manufacturing mess. Article

And Finally... France reported its first case of a novel coronavirus, similar to SARS, that has been spreading in Saudi Arabia. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.